Abstract: A carrier structure is provided, in which at least one positioning area is defined on a chip-placement area of a package substrate, and at least one alignment portion is disposed on the positioning area. Therefore, the precision of manufacturing the alignment portion is improved by disposing the positioning area on the chip-placement area, such that the carrier structure can provide a better alignment mechanism for the chip placement operation.

Abstract: A radioactive material for inhibiting cancer and a preparation method thereof are disclosed. The radioactive material for inhibiting cancer is M-SOCTA-Z and M is a radioactive nuclide such as 188Re or 99mT while Z is protein or peptides having amino acid with NH or NH2 group. The preparation method of the radioactive material for inhibiting cancer includes steps of: reacting SOCTA with protein or peptide. Ester (—COOR) in SOCTA reacts with amines (—NH, —NH2) in protein or peptide to form peptide bond. Thus SOCTA-protein or SOCTA-peptide complex is produced. Then these SOCTA-protein complex reacts with radioactive nuclide M so as to generate M-SOCTA-protein or M-SOCTA-peptide. In an embodiment of the present invention, monoclonal antibody Herceptin is applied to bind with SOCTA and in combination with radiation-based therapy, effects of cancer treatment (such as breast cancer) are enhanced.

Abstract: This invention relates to novel optically active 3-substituted methyl-5-methylthio-2,3-dihydroimidazo?1,2-c!quinazoline (I) and 3-substituted methyl-2,3-dihydroimidazo?1,2-c!quinazolin-5(6H)-one (II). This invention also relates to the therapeutical use of these novel compounds ##STR1## wherein: R is halogen, hydrogen, methoxy, trifluoromethyl, C.sub.1 -C.sub.4 alkyl, nitro, acetyl, cyano or hydroxy group; or pharmaceutically acceptable salts thereof.